Table of Contents
Overview
New York, NY – June 25, 2025 – Global C-Reactive Protein Testing Market size is expected to be worth around US$ 7.1 Billion by 2034 from US$ 5.1 Billion in 2024, growing at a CAGR of 3.4% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 32.2% share with a revenue of US$ 1.6 Billion.
The global C-Reactive Protein (CRP) Testing market is witnessing steady growth, driven by increasing prevalence of inflammatory disorders, cardiovascular conditions, and growing emphasis on preventive diagnostics. CRP testing, a key biomarker used to detect systemic inflammation, is widely employed in clinical practice to assess infections, autoimmune conditions, and cardiovascular risk.
As of 2024, healthcare providers are increasingly adopting high-sensitivity CRP (hs-CRP) assays to evaluate low-grade inflammation linked with heart disease and metabolic syndromes. The World Health Organization (WHO) highlights that cardiovascular diseases remain the leading cause of global deaths, accounting for over 17 million fatalities annually. CRP tests aid in risk stratification, enabling early therapeutic interventions and long-term patient monitoring.
The growing availability of point-of-care testing devices and automated laboratory analyzers is also enhancing accessibility and turnaround time for CRP diagnostics. Integration of CRP testing into routine health checks and emergency diagnostics is contributing to consistent market demand. Furthermore, the development of multiplex panels combining CRP with other biomarkers is improving diagnostic precision for chronic and acute inflammatory states. With increasing healthcare awareness, technological advancements, and supportive clinical guidelines, the CRP testing market is expected to remain a vital component of global diagnostic infrastructure in the coming years.
Key Takeaways
- Market Size: The global C-Reactive Protein (CRP) Testing market is projected to grow from USD 5.1 billion in 2024 to approximately USD 7.1 billion by 2034.
- Market Growth: The market is expected to expand at a compound annual growth rate (CAGR) of 3.4% between 2025 and 2034.
- Assay Type Analysis: Immunoturbidimetric assays accounted for the largest revenue share in 2024, contributing 29.3% to the total market, driven by widespread clinical adoption.
- Detection Range Analysis: High-sensitivity CRP (hs-CRP) tests dominated in 2024, holding a 42.5% market share due to their use in cardiovascular and chronic inflammation risk assessments.
- End-Use Analysis: The cardiovascular disease segment emerged as the leading application area, representing 28.3% of total revenue in 2024, owing to increasing use of CRP testing in cardiac risk stratification.
- Regional Analysis: North America led the global CRP testing market in 2024, securing a 32.2% share and generating approximately USD 1.6 billion in regional revenue, supported by advanced healthcare infrastructure and routine preventive screening practices.
Segmentation Analysis
- Assay Type Analysis: The CRP testing market is segmented into immunoturbidimetric assays, ELISA, chemiluminescence immunoassays, and others. In 2024, immunoturbidimetric assays led with a 29.3% market share due to rapid processing and suitability for high-volume labs. ELISA offered high sensitivity for research use, while chemiluminescence gained adoption for its low detection limits. Other formats, including point-of-care tests, contributed to market flexibility, catering to varied diagnostic environments and infrastructure levels.
- Detection Range Analysis: By detection range, the CRP testing market includes high-sensitivity CRP (hs-CRP), conventional CRP, and cardiac-specific CRP (cCRP). hs-CRP led in 2024 with 42.5% share, widely used for cardiovascular risk prediction and low-grade inflammation assessment. Conventional CRP remained essential for routine infection and inflammation testing. cCRP gained clinical relevance in cardiology for monitoring acute events. This segmentation reflects the tailored use of CRP assays based on sensitivity needs and specific disease applications.
- Cardiovascular Diseases Analysis: CRP testing is applied in cardiovascular diseases, cancer, rheumatoid arthritis, IBD, endometriosis, lupus, and others. In 2024, cardiovascular diseases held the largest share at 28.3%, driven by high-sensitivity CRP’s role in early cardiac risk assessment. Cancer and autoimmune conditions followed, using CRP for inflammation tracking and treatment monitoring. Other uses like infections and surgical recovery further support CRP’s clinical value across a broad spectrum of medical applications.
Market Segments
By Assay Type
- Immunoturbidimetric Assay
- ELISA
- Chemiluminescence Immunoassay
- Others
By Detection Range
- hs-CRP
- Conventional CRP
- cCRP
By Disease Area
- Cardiovascular Diseases
- Cancer
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Endometriosis
- Lupus
- Others
Regional Analysis
In 2024, North America led the global C-Reactive Protein (CRP) testing market with a 32.2% share, valued at USD 1.6 billion. This dominance is supported by a high burden of chronic and inflammatory conditions. In 2023, chronic pain affected 24.3% of U.S. adults, while diagnosed arthritis impacted 18.9% in 2022. The economic burden of cardiovascular disease, estimated at USD 129.3 billion during 2020–2021, has further driven demand for high-sensitivity CRP (hs-CRP) assays for early risk assessment.
Europe held a significant market share, particularly in Western countries, where updated screening guidelines incorporated hs-CRP testing for cardiovascular risk. Public health campaigns and favorable reimbursement policies contributed to stable market growth, accounting for nearly one-fourth of the global share.
Asia Pacific recorded the fastest market expansion due to rising healthcare spending, improved diagnostics infrastructure, and a growing burden of cardiovascular diseases affecting an estimated 523 million people in 2020. Government-led early detection programs also played a key role.
Latin America and the Middle East & Africa held the remaining market share, with increasing adoption of CRP testing for infection control and chronic disease monitoring. Cost-effective point-of-care solutions and investments in laboratory infrastructure supported growth in these emerging regions.
Emerging Trends
- Adoption of High-Sensitivity CRP (hs-CRP) Assays for Cardiovascular Risk Stratification: The growth of hs-CRP testing can be attributed to its role in pinpointing individuals at elevated risk for cardiovascular events. These assays measure CRP levels as low as 0.1 mg/dL, enabling stratification into low (< 1.0 mg/dL), average (1.0–3.0 mg/dL), and high (> 3.0 mg/dL) risk categories for future heart disease. Clinical guidelines from the CDC and American Heart Association now include hs-CRP as an adjunct to traditional risk factors, driving wider laboratory adoption.
- Expansion of Point-of-Care CRP Testing for Infection Triage: Point-of-care CRP devices, which require only a finger-prick sample, are increasingly deployed in primary care and low-resource settings. Performance data from six studies across Kenya, South Africa, and Uganda (total n = 3,971) demonstrate that capillary CRP testing can detect active tuberculosis with an average prevalence of 14% (range: 1–26%). In HIV clinics, CRP screening at a > 5 mg/L threshold achieved sensitivity of 89% and specificity of 54%, surpassing symptom-based screens (sensitivity 84%, specificity 37%).
- CRP Monitoring in COVID-19 and Multisystem Inflammatory Syndromes: During the COVID-19 pandemic, rising CRP has been routinely used to gauge disease severity and inflammatory complications. Elevated CRP correlates with poor prognosis and need for intensive care in hospitalized patients, guiding treatment escalation. In children, CRP levels > 3.0 mg/dL distinguish multisystem inflammatory syndrome in children (MIS-C) from acute COVID-19 and Kawasaki disease, with most MIS-C patients exceeding this threshold.
Use Cases
- Cardiovascular Risk Assessment: hs-CRP measurement augments traditional risk scores by quantifying low-grade inflammation. According to CDC/AHA guidelines, individuals with CRP < 1.0 mg/dL are at low risk, those with 1.0–3.0 mg/dL at average risk, and > 3.0 mg/dL at high risk for future cardiovascular events. This numeric stratification informs preventive strategies, such as statin therapy, and is used in over 60% of U.S. lipid clinics.
- Tuberculosis Screening among People Living with HIV: In resource-limited HIV care settings, CRP testing serves as an initial screen for active tuberculosis. The WHO recommends a CRP cut-off of > 5 mg/L, which achieves a pooled sensitivity of 89% (95% CI: 73–90%) and specificity of 64% (95% CI: 55–72%) when used sequentially after symptom screening. This approach can reduce unnecessary diagnostic tests by up to 40%, optimizing use of Xpert MTB/RIF assays.
- Monitoring Inflammatory Syndromes in Pediatrics: CRP testing is integral to diagnosing MIS-C after SARS-CoV-2 infection. Surveillance data indicate that among 117 MIS-C cases in 2023, approximately 50% required ICU care; most exhibited CRP > 3.0 mg/dL, compared to lower elevations in acute COVID-19. Rapid CRP measurement helps clinicians differentiate MIS-C from other febrile illnesses, enabling timely immunomodulatory therapy.
- Routine Infection and Inflammation Management: Beyond specialized uses, CRP assays assist in monitoring treatment response in bacterial infections, autoimmune flares, and postoperative inflammation. Quantitative CRP guides antibiotic stewardship by indicating when to discontinue therapy, with a ≥ 75% drop in CRP over 5–7 days correlating with resolution of bacterial infections in over 80% of cases. Clinicians across inpatient and outpatient settings employ CRP trends to tailor patient care.
Conclusion
The global C-Reactive Protein (CRP) testing market is positioned for sustained growth, supported by its clinical utility in cardiovascular, infectious, and inflammatory diseases. The increasing adoption of high-sensitivity CRP (hs-CRP) assays, expansion of point-of-care diagnostics, and integration into routine health evaluations continue to drive market demand.
Regional uptake, especially in North America and Asia Pacific, reflects the growing need for early detection tools and chronic disease management. With supportive clinical guidelines and advancements in assay technologies, CRP testing remains a crucial component of preventive healthcare and personalized medicine, ensuring its relevance across a broad spectrum of medical applications.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
